Thyroid-related laboratory abnormalities to predict treatment-limiting adverse events in melanoma patients treated with immune checkpoint blockade.

被引：2
|
作者：
Altman, Daniel
Weight, Ryan Michael
Shah, Mansi R.
Orloff, Marlana M.
Sharpe-Mills, Erin
Mastrangelo, Michael J.
Sato, Takami
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA USA
[2] Thomas Jefferson Univ Hosp, Philadelphia, PA USA
[3] Thomas Jefferson Univ, Dept Med Oncol, Kimmel Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e14536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14536
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Neurologic immune related adverse events (irAEs) in patients treated with immune checkpoint blockade.
    Santomasso, Bianca
    Haggiagi, Aya
    Malani, Rachna
    Maher, Colleen Anne
    Holder, Jenessa N.
    Shames, Yelena
    Wilcox, Jessica
    Flynn, Jessica
    Briggs, Samuel
    Panageas, Katherine
    Callahan, Margaret K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
    de Filette, Jeroen
    Jansen, Yanina
    Schreuer, Max
    Everaert, Hendrik
    Velkeniers, Brigitte
    Neyns, Bart
    Bravenboer, Bert
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (11): : 4431 - 4439
  • [3] Thyroid-related adverse events induced by immune checkpoint inhibitors
    Chera, Alexandra
    Stancu, Andreea Lucia
    Bucur, Octavian
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [4] The prognostic impact of immune-related adverse events in real-world patients with metastatic melanoma treated with single-agent and combination immune checkpoint blockade.
    Watson, Alexander
    Goutam, Siddhartha
    Stukalin, Igor
    Ewanchuk, Benjamin
    Sander, Michael
    Meyers, Daniel E.
    Pabani, Aliyah
    Cheung, Winson Y.
    Heng, Daniel Yick Chin
    Cheng, Tina
    Monzon, Jose Gerard
    Navani, Vishal
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
    Mykhaylo Usyk
    Abhishek Pandey
    Richard B. Hayes
    Una Moran
    Anna Pavlick
    Iman Osman
    Jeffrey S. Weber
    Jiyoung Ahn
    Genome Medicine, 13
  • [6] Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma
    Usyk, Mykhaylo
    Pandey, Abhishek
    Hayes, Richard B.
    Moran, Una
    Pavlick, Anna
    Osman, Iman
    Weber, Jeffrey S.
    Ahn, Jiyoung
    GENOME MEDICINE, 2021, 13 (01)
  • [7] Immune-Related Thyroid Adverse Events Predict Response to PD-1 Blockade in Patients with Melanoma
    Dawidowska, Anna
    Jagodzinska-Mucha, Paulina
    Kosela-Paterczyk, Hanna
    Jaczewska, Sylwia
    Sobczuk, Pawel
    Chelstowska, Monika
    Kowalska, Maria
    Badziak-Sterczewska, Honorata
    Poleszczuk, Jan
    Rutkowski, Piotr
    Lugowska, Iwona
    CANCERS, 2022, 14 (05)
  • [8] Rechallenging with immune checkpoint inhibition after a treatment-limiting immune-related adverse event.
    O'Neal, Richard Lee
    Roberts, Kandice
    Hao, Zhonglin
    Arnold, Susanne M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors
    Gault, A.
    Anderson, A. E.
    Plummer, R.
    Stewart, C.
    Pratt, A. G.
    Rajan, N.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (02) : 263 - 271
  • [10] Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
    Weinmann, Sophia
    Eudy, Amanda
    Pisetsky, David
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3174 - 3175
12345